Kantar Health Blog

  • User Not Found
    Pricing a drug is a hugely important aspect of pre-launch and launch planning as it can directly influence market share. Forecasting the dollar value of an oncology drug presents many challenges and caveats and takes into account price, duration of therapy, the eligible population, and market share of the eligible population.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight - ASCO GI 2013 With recent news being so heavily centered on targeted agents, it seems as though people often forget about the value that chemotherapy has provided over the years and, more importantly, that there is still room for improvement in these older regimens to generate significantly better outcomes for patients. Celgene was looking to take advantage of this sentiment when the company acquired Abraxis BioScience and their leading drug candidate, Abraxane®, an injectable suspension of nanoparticle albumin bound (nab)-paclitaxel.
    Continue Reading > | Go comment! | Share
  • Neesha Suvarna
    Oncology Conference Insight - ASCO GI 2013 Will ramucirumab be able to show an additive benefit when combined with an active agent in a tumor type where Avastin failed to do so? This is a huge unanswered question for ramucirumab: is the mechanism of action different enough to surpass the activity of Avastin?
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight Blogs - ASH 2012 Pomalidomide is a next-generation immunomodulatory agent in development for relapsed/refractory multiple myeloma, designed to follow in the footsteps of its siblings, Revlimid (lenalidomide, Celgene) and Thalomid (thalidomide, Celgene). In spite of the increased competition, pomalidomide will be eagerly included into the drug armamentarium for myeloma patients.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight Blogs - ASH 2012: The combination of CHOP plus Rituxan (rituximab, Genentech/Roche; R-CHOP) has been the traditional standard of care in the United States and Europe for follicular lymphoma (FL) and mantle cell lymphoma (MCL). That regimen is associated with a range of adverse effects, including cardiac, hematologic, and neurologic toxicity, as well as infectious complications. Many physicians feel that CHOP has a role in treating more aggressive diseases such as diffuse large B-cell lymphoma, but debate as to whether such an aggressive regimen is warranted for treatment of patients with indolent lymphomas.
    Continue Reading > | Go comment! | Share